GlassScriptPhysician profile
Nikhil Deshpande
NPI 1003869041
$1,207.41
in general payments reported to CMS, 2019-2025
17 companies · $520 in 2025
The $520 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $111 · 2021: $53.94 · 2022: $29.20 · 2023: $61.36 · 2024: $225 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $767 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $766.78 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $430.29 | 2019-2025 | Xifaxan |
| Abbvie INC. | $202.88 | 2019-2025 | Linzess, Viberzi |
| Janssen Biotech, INC. | $76.81 | 2019-2024 | Simponi, Simponi Aria, Stelara |
| Amgen INC. | $73.44 | 2025 | Uplizna |
| Phathom Pharmaceuticals, INC. | $66.27 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $58.37 | 2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $55.65 | 2024-2025 | Dupixent |
| Genzyme Corporation | $48.16 | 2023-2024 | |
| Madrigal Pharmaceuticals | $38.13 | 2025 | Rezdiffra |
| Pfizer INC. | $32.86 | 2025 | |
| Ferring Pharmaceuticals INC. | $30.17 | 2019-2023 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $22.14 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $16.68 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.15 | 2019 | |
| Allergan, INC. | $13.93 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $13.44 | 2020 | |
| Alfasigma USA, INC. | $13.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhil Deshpande listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.